JOSEPH BROWN: Open Payments
NPI 1245908292 · CABOT, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,036 in 58 payments from 12 companies in 2025. Trend: 2023 $790 · 2024 $1,640 · 2025 $1,036
Food & beverage: $1,036
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $320 |
| AstraZeneca Pharmaceuticals LP | 11 | $200 |
| Lilly USA, LLC | 9 | $144 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $84 |
| Novo Nordisk Inc | 5 | $76 |
| Phathom Pharmaceuticals, Inc. | 3 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Merck Sharp & Dohme LLC | 2 | $33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31 |
| Amgen Inc. | 2 | $28 |
Products named: MOUNJARO, AIRSUPRA, VRAYLAR, UBRELVY, XIFAXAN, QULIPTA, Ozempic, VOQUEZNA.
Industry payments across AR — which companies pay providers there.
